Stromal FOXF2 Suppresses Prostate Cancer Progression and Metastasis by Enhancing Antitumor Immunity
Researchers showed that increasing prostatic stromal Foxf2 suppressed the growth and progression of both syngeneic and autochthonous mouse prostate cancer models in an immunocompetent context.
[Haematologica] 301 patients with a median age 60 years were enrolled. Of them, 287 and 274 patients collected ≥2 and ≥4×106 CD34+ cells/kg, respectively, with a median of 9.9×106 CD34+ cells/kg collected.
[EMBO Journal] The authors provide an in-depth review of the metabolic and epigenetic interplay regulating hematopoietic stem cell fate, and discuss the influence of metabolic stress stimuli, as well as alterations occurring during leukemic development.